このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (ATLAS)

2026年5月29日 更新者:GlaxoSmithKline

A Randomized Phase 2/3, Double-blind, Placebo Controlled Adaptive Study Evaluating the Efficacy and Safety of Momelotinib in Participants With VEXAS Syndrome

This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.

調査の概要

状態

まだ募集していません

研究の種類

介入

入学 (推定)

136

段階

  • フェーズ2
  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Age greater than equal to (>=)18 years OR of legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the Informed Consent Form.
  • Confirmed diagnosis of clinical VEXAS defined by:

    1. Documented evidence of a canonical, pathogenic Ubiquitin-like modifier activating enzyme 1 (UBA1) mutation
    2. Inflammatory manifestations: current or documented past involvement within 6 months of at least one organ system
  • Receiving glucocorticoid (GC) treatment (prednisone/prednisolone) for >=4 consecutive weeks for >=10 days prior to randomization.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:

    1. Is a Participant of non-childbearing potential (PONCBP) OR
    2. Is a Participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2 at the time of screening.
  • Has adequate organ function

Exclusion Criteria:

  • More than 1 prior admission to an intensive care unit due to a VEXAS flare within the 6 months prior to randomization.
  • History of severe corticosteroid toxicity: uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), psychiatric, osteoporosis/osteomalacia, glaucoma, corneal ulcers/injuries, nausea or vomiting or gastrointestinal disease.
  • High risk/very high risk Myelodysplastic syndrome (MDS), according to the Revised International Prognostic Scoring System (IPSS-R) with overall risk score >3.5.
  • Peripheral blood blast counts >=10%.
  • Multiple myeloma (all stages) and other active plasma cell dyscrasias requiring treatment.
  • Malignancy (except disease under study including Lower-risk myelodysplastic syndrome [LR-MDS]) that has progressed or required active treatment within the past (24 months) except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas).
  • Uncontrolled intercurrent illness within 12 weeks prior to initiation of momelotinib.
  • Ongoing adverse reaction(s) from prior therapy that have not recovered to Grade <=1 per NCI CTCAE v6.0 or to the Baseline status preceding prior therapy
  • Psychiatric illness, social situation, or any other condition that would limit informed consent and/or compliance with trial requirements or may interfere with the interpretation of study results, as judged by Investigator or Sponsor.
  • Has any clinically significant gastrointestinal conditions or abnormalities that may alter absorption or swallowing
  • Known contraindication or hypersensitivity to momelotinib and its metabolites, or any of their excipients.
  • Presence of peripheral neuropathy >=Grade 2 per NCI CTCAE v6.0.
  • Known history of disseminated mycobacterial infection.
  • Known positive status for human immunodeficiency virus (HIV).
  • Positive QuantiFERON (or other interferon gamma release assay) during Screening.
  • Unable to receive any Pneumocystis jiroveci pneumonia (PJP) medical prophylaxis
  • Known clinically significant anemia due to iron, vitamin B12 or folate deficiencies, or autoimmune or hereditary hemolytic anemia, gastrointestinal bleeding, or thalassemia.
  • More than 1 prior line of VEXAS directed therapy before or after VEXAS diagnosis or other medical condition.
  • Use of the following treatments within the noted time periods referenced from date of randomization:

    1. VEXAS-directed therapies (washout period) up to 5 half-lives or up 14 days if half-life is <3 days
    2. Other non-GC anti-inflammatory therapies: for non-biologics): 14 days or five half-lives, whichever is longer; for biologics): 28 days or two half-lives whichever is longer.
    3. Hematologic support therapy (e.g., ESAs, danazol, luspatercept, G-CSF): 4 weeks
    4. Cell-depleting therapies such as anti-CD20 (rituximab): 12 months
    5. Investigational agent from a class not otherwise specified: 5 half-lives or 60 days, whichever is longer
  • GC use for conditions other than VEXAS, which would interfere with adherence to the fixed GC taper regimen and/or to assessment of efficacy.
  • Chronic use of systemic corticosteroids for >4 years or inability to withdraw corticosteroid treatment
  • Planned allogeneic HSCT for MDS or VEXAS, within 1 year.
  • Any major surgery within 28 days prior to randomization.
  • Prior allogeneic/autologous stem cell transplant or solid organ transplant (other than corneal).
  • Presence of peripheral neuropathy >=Grade 2 per NCI CTCAE v6.0.
  • Hepatitis B or C active infection, unless protocol defined criteria are met.
  • Any of the following conditions within 6 months prior to randomization:

    1. Unstable angina pectoris
    2. Symptomatic congestive heart failure
    3. Uncontrolled cardiac arrhythmia
    4. QTc >450 msec or QTc >480 msec for participants with bundle branch block.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Momelotinib Dose level 1 + Glucocorticoids
Participants will receive momelotinib at dose level 1 along with glucocorticoids as a background therapy (prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3.
Momelotinib will be administered
他の名前:
  • GSK3070785
Glucocorticoids (prednisone or prednisolone) will be administered
実験的:Momelotinib Dose level 2 + Glucocorticoids
Participants will receive momelotinib at dose level 2 along with glucocorticoids as a background therapy (prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3
Momelotinib will be administered
他の名前:
  • GSK3070785
Glucocorticoids (prednisone or prednisolone) will be administered
プラセボコンパレーター:Placebo + Glucocorticoids
Participants will receive momelotinib matched placebo along with glucocorticoids as a background therapy(prednisone or prednisolone). Due to adaptive design of the study, additional participants may be randomized to this arm in phase 3
プラセボが投与されます
Glucocorticoids (prednisone or prednisolone) will be administered

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
ORR (Objective response rate) at Week 26
時間枠:At Week 26
ORR is defined as the proportion of participants who have achieved complete response (CR) or partial response (PR) during the 26-week Primary Treatment Period.
At Week 26

二次結果の測定

結果測定
メジャーの説明
時間枠
Phase 2: Percentage of participants with partial response (PR) or complete response (CR) at Week 26
時間枠:At Week 26
Percentage of participants with PR or CR at Week 26 to support identification of the Recommended Phase 3 dose (RP3D)
At Week 26
Phase 2: Number of participants with adverse events and clinically significant changes in laboratory parameters, and vital signs to support identification of the RP3D
時間枠:Up to 26 Weeks
Up to 26 Weeks
Phase 2: Plasma concentrations of momelotinib and metabolite of momelotinib 21 (M21) to support identification of the RP3D
時間枠:Up to 26 Weeks
Up to 26 Weeks
Number of flare-free days
時間枠:Up to 26 Weeks
Flare-free days are calendar days without clinical evidence of VEXAS flare and without treatment escalation. Total number of flare-free days is defined as the cumulative number of consecutive and non-consecutive flare-free days.
Up to 26 Weeks
Duration of response (DoR)
時間枠:Up to 104 Weeks
DoR defined as the date of clinical response (CR or PR) to the date of relapse.
Up to 104 Weeks
Number of flare-free days with glucocorticoid (GC) dose <=10 mg/day
時間枠:Up to 104 Weeks
Flare-free days are calendar days without clinical evidence of VEXAS flare and without treatment escalation. Total number of flare-free days is defined as the cumulative number of consecutive and non-consecutive flare-free days.
Up to 104 Weeks
Percentage of participants achieving complete and partial biochemical response
時間枠:Up to 26 Weeks
Complete biological response is defined as complete or partial normalization of C-reactive protein.
Up to 26 Weeks
Objective response rate (ORR) at Week 52
時間枠:At Week 52
ORR is defined as the proportion of participants who have achieved complete response or partial response
At Week 52
Number of Participants with Hematologic Improvement- Erythroid (HI-E) response per International Working Group (IWG) 2018 criteria
時間枠:Up to 26 Weeks
HI-E response is measured based on the combined incidence of: Low transfusion burden participants defined as absence of any transfusion for greater than or equal to (>=)8 consecutive weeks. High transfusion burden participants: minor response defined as reduction by >=50% of red blood cell (RBC) units for >=8 consecutive weeks. Major response defined as absence of RBC transfusions for >=8 consecutive weeks or longer up to 26 weeks.
Up to 26 Weeks
Change from Baseline in Short Form 36 (SF-36) domain and summary scores
時間枠:Baseline and up to Week 48
Short-Form 36 is a health-related survey that assesses quality of life covering 8 domains: vitality; physical functioning; bodily pain; general health perceptions; physical role functioning; emotional role functioning; social role functioning; and mental health. The domain scores are weighted to a scale ranging between 0 to 100, where higher score represents better health. The Physical Component Summary (PCS) and Mental Component Summary (MCS) scores are derived from the eight domain scores. These scores are standardized to a general U.S. population average of 50, with a standard deviation of 10. For both PCS and MCS, scores range from 0 to 100, higher scores indicate a better health outcome.
Baseline and up to Week 48
Change from Baseline in European Organization for Research and Treatment of Cancer Item Library (EORTC IL) 479 score
時間枠:Baseline and up to Week 156
The EORTC Item Library is a database containing >1000 individual items from more than 70 EORTC quality of life measures. A subset of 7 items from the library were selected based on symptoms experienced by participants with VEXAS syndrome. Scores range from 1 to 100 with higher scores representing a higher ("worse") level of symptoms.
Baseline and up to Week 156
Change From Baseline in Patient Reported Outcome Measurement Information System (PROMIS) Physical Function Short Form 10b
時間枠:Baseline and up to Week 156
PROMIS Physical Function Short Form 10b consists of 10 questions; each with a 5-point response. PROMIS short form assesses self-reported capability of a participant rather than actual performance of physical activities. Higher scores indicate better functioning. Total possible range of scores is 10 to 50, with higher scores corresponding to a greater physical function ability.
Baseline and up to Week 156
Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-FATIGUE)
時間枠:Baseline and up to Week 156
The FACIT-Fatigue is a short, 13-item questionnaire that assesses self-reported fatigue and its associated impact on daily activities over the past 7 days. A higher score indicates a better outcome (no fatigue). The total score ranges from 0 to 52, with 0 being the worst possible score and 52 being the best possible score (indicating no fatigue).
Baseline and up to Week 156
Changes from Baseline in Patient Global Impression of Severity (PGIS) scores
時間枠:Baseline and up to Week 156
The PGIS is a single global question which asks participants to rate the severity of their VEXAS syndrome symptoms on a 5-point rating scale with response categories of "No symptoms", "Mild", "Moderate", "Severe", and "Very Severe." The PGIS scores ranges from 0 (absent) to 4 (very severe).
Baseline and up to Week 156
Changes in Patient Global Impression of Change (PGIC) scores
時間枠:Baseline and up to Week 156
The PGIC is a single global question which asks participants to rate the change in severity of their VEXAS syndrome symptoms since starting study medication using a 5-point rating scale with response categories of "much better", "a little better", "no change", "a little worse", "much worse". The PGIC score ranges from +2 (much better) to -2 (much worse).
Baseline and up to Week 156
Changes from Baseline in European quality of life 5 dimensions 5 level version (EQ-5D-5L)
時間枠:Baseline and up to Week 48
EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by 5-point Likert scale ranging from 1=no problems to 5=extreme problems.
Baseline and up to Week 48
Changes from Baseline in European quality of life-Visual Analogue Scale (EQ-VAS)
時間枠:Baseline and up to Week 48
The EQ-VAS records the respondents self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health.
Baseline and up to Week 48
Number of participants with adverse events (AEs) and Serious adverse events (SAEs)
時間枠:Up to Week 108
Up to Week 108
Number of participants with adverse events (AEs) and Serious adverse events (SAEs) by severity
時間枠:Up to Week 108
Up to Week 108
Number of participants with AEs leading to discontinuation or dose modifications
時間枠:Up to Week 108
Up to Week 108
Plasma concentration of momelotinib and M21
時間枠:Up to 26 Weeks
Up to 26 Weeks
Overall Survival
時間枠:At Months 12, 24 and 36
Overall survival is defined as the time from randomization to the date of death due to any cause.
At Months 12, 24 and 36

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:GSK Clinical Trials、GlaxoSmithKline

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月5日

一次修了 (推定)

2028年12月6日

研究の完了 (推定)

2031年6月4日

試験登録日

最初に提出

2026年4月28日

QC基準を満たした最初の提出物

2026年4月28日

最初の投稿 (実際)

2026年5月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月1日

QC基準を満たした最後の更新が送信されました

2026年5月29日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する